MD-FM logo

Dr Valentin Goede: New anti CD-20 agent for the treatment of CLL

Download Podcasts
Download Podcasts
You can select your prefered subtitle language by using the  CC  button in the player control bar.
English

Dr Valentin Goede:

New anti CD-20 agent for the treatment of Chronic Lymphocytic Leukemia

 

 

CLEMENTINE:

Hello! You’re on MD-FM INSIGHT, the first medical web radio. Today we’ll be devoting our "Question & Answer" program to the treatment of Older patients with Chronic Lymphocytic Leukemia (or CLL), the most common type of leukemia in-adults.

 

Currently, the anti-CD-20 monoclonal antibody rituximab is a standard of care for these patients. A second anti-CD-20 antibody, ofatumumab came out in 2012, and now a third one, obinutuzumab, at the end of last year. Trials are currently ongoing to compare their safety and efficacy in different settings.

 

At the 2013 annual meeting of the American Society of Hematology, which took place last December in New Orleans, Dr. Valentin Goede, an hematologist from the University Hospital in Cologne, Germany, presented the results of a head to head comparison between obinutuzumab and rituximab, in older CLL patients with comorbidities. Dr. Goede then gave MD-FM the details…

 

CLEMENTINE:

Hello Dr. Goede, first of all, could you give me an overview of this latest anti-CD-20 agent?

 

GOEDE:

“This new compound is obinutuzumab, or GA-101, this is a novel CD-20 antibody, a type 2 antibody, which means that the biding region of this antibody has been modified and this antibody also has a glyco-engineered FC region and, in pre-clinical studies, it has been shown that these 2 antibody features result in higher efficacy against CLL cells than rituximab, which is the current standard of care.”

 

CLEMENTINE:

Tell us about the study you just presented during the plenary session?  

 

GOEDE:

“Here actually we are presenting the results of the head-to-head comparison of the GA-101 arm and the rituximab arm of our CLL-11 study, and the main result is that GA-101 in combination with chlorambucil is superior to rituximab in this combination, with regards to the primary endpoint of the trial, which was progression-free survival, but also with regards to various secondary endpoints, mainly complete remissions and also absence of molecular disease in the marrow or in the blood of a patient after the end of treatment.”

 

CLEMENTINE:

Any safety issues associated with GA-101?

 

GOEDE:

“In terms of safety we can say that GA-101 in combination with chlorambucil has an acceptable safety profile, there is one defined risk, becoming obvious with this trial, and this risk is infusion-related reactions occurring with the first infusion of that new antibody. And it is important that doctors know about this, that they do prophylactic measures and that they monitor the patient carefully during the first infusion of this drug. The subsequent infusions will be normally without any problems.”

 

CLEMENTINE:

So what’s your take-home message regarding the perspectives for hematologists?

 

GOEDE:

“First I think we can say that GA-101 and chlorambucil represents a significant advance in the treatment of elderly patients with CLL. And then one can also draw some more general conclusions: one can say that this study has shown that the specific antibody features improve anti-CD20 therapy in CLL, generally, obviously, and that also maybe that the induction of deeper remissions in these patients obviously changes the course of the disease and can result in overall survival so that our concept to treat these patients may expand from pure symptom control to long-lasting disease control.”

 

Clementine:

This show is over. By visiting the MD-FM website, you can check out the themes of the programs we will be offering you regularly.

See you soon on MD-FM.

RSS
Twitter
Facebook

Previous editions

Partnership

Best of Science in Nutrition 2013: Yogurt for a healthier diet (EB & IUNS 2013)

Best of Science in Nutrition 2013: Yogurt for a healthier diet (EB & IUNS 2013)
Url
Go to
with
Danone Institute International